

Date: 18th December 2024

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400 001
Scrip Code-531599

National Stock Exchange of India Ltd.

Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E),
Mumbai - 400 051
NSE Symbol- FDC

Ref.: Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/ Madam,

This is further to the intimation given by the Company dated 13th November, 2024, with regard to US FDA inspection at Company's manufacturing facility located at Baddi, Himachal Pradesh.

We are pleased to announce that the Company has received final approval from US FDA for the Company's Abbreviated New Drug Application (ANDA) for Cefixime 400 mg Tablets.

Kindly take the above on record.

Thanking you,

Yours truly,

For FDC LIMITED

Varsharani Katre
Company Secretary & Compliance Officer
Membership No.: FCS-8948